Brielle Benyon

The Food and Drug Administration approved Brukinsa plus Gazyva for patients with relapsed or refractory follicular lymphoma who have undergone two or more prior lines of therapy.

The time after a cancer diagnosis can be stressful, as the care team needs to balance unnecessary treatment delays with getting the therapeutic plan right.

The Food and Drug Administration approved Besponsa for pediatric patients aged 1 and older with relapsed or refractory CD22-positive, B-cell precursor ALL.

Lutathera plus Sandostatin improved progression-free survival in patients with advanced gastric neuroendocrine tumors, research showed.

In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.

The Food and Drug Administration approved Rybrevant plus carboplatin and pemetrexed for locally advanced or metastatic non-small cell lung cancer (NSCLC) that has EGFR exon 20 insertion mutations.

From TikTok singer Cat Janice dying of cancer to Taylor Swift giving a 9-year-old with brain cancer the “22” hat during a recent concert, here is what’s happening in the oncology space this week.

Consulting physical therapy early on and speaking up to the health care team can help patients with blood cancer be more prepared for a hematopoietic stem cell transplant, an expert said.

An oral suspension formula of Imbruvica received the green light from the Food and Drug Administration to be used in all approved indications.

After Tepmetko’s full approval for metastatic lung cancer treatment, patients should feel that the data from the accelerated approval is validated, an expert said.

The FDA granted a breakthrough therapy designation to BAY 2927088 after it showed promise in treating patients with HER2 mutations.

February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.

Patients who were obese tended to have an increased risk of moderate to severe GVHD after undergoing allogeneic hematopoietic cell transplantation, research showed.

Treatment with rusfertide led to a decrease in the need for blood draws and decreased levels of red blood cells in patients with polycythemia vera.

From Ben Lanzarone of “Happy Days” and “Grease” dying of lung cancer to “Good Morning America’s” Michael Strahan providing an update on his daughter’s medulloblastoma treatment, here’s what’s happening in the oncology space this week.

While posttransplant Xospata did not worsen quality of life in patients with acute myeloid leukemia, it is essential that patients tell their providers about any side effects that they experience, an expert said.

Treatment with Amtagvi, a TIL therapy recently approved for advanced melanoma, includes a three-week hospital stay upfront, but may lead to years of monitoring without more treatment needed, an expert explained.

The Food and Drug Administration is reviewing the novel drug, linvoseltamab, for the treatment of patients with pretreated, relapsed or refractory multiple myeloma.

The Food and Drug Administration is reviewing Dato-DXd for potential approval to treat pretreated advanced nonsquamous non-small cell lung cancer.

The Food and Drug Administration granted a priority review to Krazati plus Erbitux for KRAS G12C-mutant locally advanced or metastatic colorectal cancer.

Straying away from standard-of-care chemotherapy can improve quality of life without sacrificing outcomes in older patients with advanced cancer.

Last week, we saw FDA approvals for new drug regimens, as well as some expert opinion about cancer vaccines

Prostate cancer survivors who had a more plant-based diet tended to have fewer sexual and urinary side effects, research showed.

The Food and Drug Administration approved Amtagvi, a TIL therapy, for patients with advanced melanoma whose disease progressed on or after a checkpoint inhibitor and targeted therapy.

From International Childhood Cancer Day to an Ivory Coast soccer player making a victorious comeback after testicular cancer, here’s what is happening in the oncology space this week.

The Food and Drug Administration will review Augtyro for potential approval in children and adults with advanced solid cancers that harbor NTRK gene fusions.

Patients with myeloproliferative neoplasms should keep their care team up to date on any symptoms they’re experiencing, an expert said.

Concurrent circulating tumor DNA and tissue-based testing identified more patients eligible for personalized cancer care than either of the tests done alone.

Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews

Anktiva boosted responses to BCG treatment without affecting quality of life, research showed.